Amid the relentless battle against COVID-19, the medical community continues to seek and advocate for effective treatments and preventive measures. However, controversies and debates around certain treatments have also marked this global fight. A notable instance is the use of ivermectin, an anthelmintic medication, for COVID-19 prevention and treatment. In a significant move, on September 2, 2021, the American Medical Association (AMA), together with the American Pharmacists Association (APhA) and the American Society of Health-System Pharmacists (ASHP), issued a joint statement calling for an 'immediate' end to the off-label use of ivermectin for COVID-19 outside of clinical trials. This article aims to delve into the circumstances leading to this assertion, the potential risks associated with ivermectin misuse, and the recommended preventive measures against COVID-19.
Write a comment